Chemotherapy Patient Articles & Analysis
43 news found
The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. ...
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. ...
In fact, studies have demonstrated that gemcitabine (an FDA-approved chemotherapy) administered directly via the pancreatic arteries may be associated with more than half the patients living over two years. ...
ByxCures
Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, ...
Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that LB-100 is readily ...
The clinical trial is expected to begin later this year or during the first quarter of 2023; up to 170 patients will be entered onto the trial, which is expected to be completed within two and a half years. This rapid rate of patient accrual is only possible through the collaborative efforts of GEIS ...
“Findings from the SUNLIGHT trial could potentially represent a significant advancement in the treatment of patients with metastatic colorectal cancer who have progressed after two lines of standard chemotherapy,” said Nadia Caussé-Amellal, M.D., Head of Global Development, GI Indications, Oncology and Immuno-Oncology Therapeutic Area, Servier. ...
The Cellworks platform analyzes the impact of specific therapies on the patient’s personalized disease model and generates a SingulaTM biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict the efficacy of specific chemotherapies. ...
Thirty-five patients completed treatment with 60 gray of intensity-modulated radiation therapy (IMRT) plus chemotherapy over six weeks. Of these 35 patients, 29 received at least five weeks of 90 mg of avasopasem on the days they underwent IMRT. These 29 patients were evaluated as the pre-specified per protocol population. ...
His current observations of unexpected synergy of LB-100 with a variety of standard agents and with investigational compounds with only modest activity on their own are promising leads to a new approach to cancer chemotherapy.” About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. ...
In April 2021, the FDA granted Orphan Drug Designation to CYNK-001 for the treatment of patients with malignant gliomas, including GBM. In June 2021, Celularity announced the expansion of its ongoing Phase 1 clinical trial of CYNK-001 in AML (NCT04310592) to include patients with relapsed/refractory AML (r/r AML) in addition to an ongoing trial in ...
Median overall survival was not reached in seven patients with hotspot inactivation mutations in PPP2R1A versus 6.4 months in the 21 patients without such mutations (p=0.018; HR=0.13 (95% CI: 0.02-0.95). ...
For the nearly one-quarter who were mesenchymal, survival was 2.4-fold worse compared to the remaining non-mesenchymal patients. A future diagnostic test, based upon this signature and related clinical findings, potentially may be used to ‘upstage’ patients typically receiving only surgical reduction to become candidates for the addition of radiation ...
Wound Infection Statistics Some patients who visit an urgent care clinic for cuts or lacerations may later develop an infection. ...
“We believe darolutamide has the potential to become a foundational drug for appropriate prostate cancer patients. We are committed to making this potential new treatment option in mHSPC available to patients and their treating physicians, and therefore are pursuing the fastest possible regulatory ...
ByBayer AG
CYNK-101 is being developed as a first-line treatment in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. ...
LONDON, February 7, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 201 Phase 1b trial of PolyPEPI1018, the Company’s lead product candidate, as an add-on to ...
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving ...
When looking at key risk factors for BCRL, including body weight, stage of cancer, type of cancer surgery, lymph node dissection, chemotherapy, and radiation, the benefit of using L-Dex monitoring was consistent and showed the utility of L-Dex across a large group of breast cancer ...
With data from more than 160,000 patients diagnosed with locally advanced and metastatic cancers, this robust dataset offers real-world insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey for many advanced solid tumor cancers, including non-small cell lung, breast, colon, ...